ExpreS2ion Biotech Financials
| EXPRS2 Stock | SEK 18.74 0.38 1.99% |
ExpreS2ion |
Understanding current and past ExpreS2ion Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ExpreS2ion Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in ExpreS2ion Biotech's assets may result in an increase in income on the income statement.
Please note, the presentation of ExpreS2ion Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ExpreS2ion Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ExpreS2ion Biotech's management manipulating its earnings.
ExpreS2ion Biotech Stock Summary
ExpreS2ion Biotech competes with Bavarian Nordic, BioPorto, Zaptec AS, and CBrain AS. ExpreS2ion Biotech Holding AB , through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark. ExpreS2ion Biotech operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 15 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0008348262 |
| Business Address | SCION-DTU Science Park, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.expres2ionbio.com |
| Phone | 45 22 22 10 19 |
| Currency | SEK - Swedish Kronor |
You should never invest in ExpreS2ion Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ExpreS2ion Stock, because this is throwing your money away. Analyzing the key information contained in ExpreS2ion Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
ExpreS2ion Biotech Key Financial Ratios
ExpreS2ion Biotech's financial ratios allow both analysts and investors to convert raw data from ExpreS2ion Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of ExpreS2ion Biotech over time and compare it to other companies across industries.| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Number Of Employees | 14 | |||
| Beta | 1.25 | |||
| Z Score | 84.0 |
ExpreS2ion Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ExpreS2ion Biotech's current stock value. Our valuation model uses many indicators to compare ExpreS2ion Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ExpreS2ion Biotech competition to find correlations between indicators driving ExpreS2ion Biotech's intrinsic value. More Info.ExpreS2ion Biotech Holding is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value ExpreS2ion Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ExpreS2ion Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.ExpreS2ion Biotech Systematic Risk
ExpreS2ion Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ExpreS2ion Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on ExpreS2ion Biotech correlated with the market. If Beta is less than 0 ExpreS2ion Biotech generally moves in the opposite direction as compared to the market. If ExpreS2ion Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ExpreS2ion Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ExpreS2ion Biotech is generally in the same direction as the market. If Beta > 1 ExpreS2ion Biotech moves generally in the same direction as, but more than the movement of the benchmark.
ExpreS2ion Biotech Thematic Clasifications
ExpreS2ion Biotech Holding is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
ExpreS2ion Biotech November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ExpreS2ion Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ExpreS2ion Biotech Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of ExpreS2ion Biotech Holding based on widely used predictive technical indicators. In general, we focus on analyzing ExpreS2ion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ExpreS2ion Biotech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 59.1 | |||
| Value At Risk | (9.21) | |||
| Potential Upside | 6.78 |
Complementary Tools for ExpreS2ion Stock analysis
When running ExpreS2ion Biotech's price analysis, check to measure ExpreS2ion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ExpreS2ion Biotech is operating at the current time. Most of ExpreS2ion Biotech's value examination focuses on studying past and present price action to predict the probability of ExpreS2ion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ExpreS2ion Biotech's price. Additionally, you may evaluate how the addition of ExpreS2ion Biotech to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |